RhabdoTec Overview
- Status
- Private
- Latest Deal Type
- Accelerator/Inc
- Latest Deal Amount
- $11.2K
- Investors
- 1
RhabdoTec General Information
Description
Developer of XUT intended to serve the pharmaceutical industry. The company's platform is offering a novel, quick and cost-effective alternative for the development and production of pharmaceutical agents, for example, antibiotics, anti-cancer drugs and immuno-suppressants that can be specifically reprogrammed for the development and production of novel active agents and used for synthesizing cyclic peptides with unusual building blocks, enabling pharmaceutical industry to produce drugs at a cost-effective rate and benefit human health.
Contact Information
- Frankfurt
- Germany
RhabdoTec Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Accelerator/Incubator | 06-Sep-2016 | $11.2K | 000.00 | Completed | Startup |
RhabdoTec Comparisons
Industry
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialRhabdoTec Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
0000000 0000000 | Accelerator/Incubator Backed | Fredericton, Canada | 00000 | 000000000000 | 00000 |
RhabdoTec Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Unibator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |